An infusion reaction to cetuximab.
Elizabeth S
ES
Waxman
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068818:Cetuximab; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology* / Q000451:nursing*; D004417:Dyspnea / Q000139:chemically induced; D005334:Fever / Q000139:chemically induced; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D017116:Low Back Pain / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy*; D009859:Oncology Nursing / Q000379:methods; D017410:Practice Guidelines as Topic; D014481:United States; D014581:Urticaria / Q000139:chemically induced
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab